![George Magrath](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 8 M $ al 31/05/2026
George Magrath is Chief Executive Officer & Director at Opus Genetics, Inc. since 2023 and Director at Voxeleron LLC since 2024.
Former roles include Chief Executive Officer & Director at Lexitas Pharma Services, Inc. from 2021 to 2022, Director at Implicit Bioscience, Inc. from 2022 to 2023, Medical Director at Hovione LLC from 2017 to 2020, Director-Translational Research Acceleration at The Foundation Fighting Blindness, Inc. from 2022 to 2023, and Analyst at Edison Investment Research, Inc. Education includes a doctorate from The Medical University of South Carolina, an MBA from The Citadel, The Military College of South Carolina in 2011, graduate studies at The Johns Hopkins University in 2016, and an undergraduate degree from Clemson University in 2006.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
OPUS GENETICS, INC. 2,14 % | 23/04/2026 | 1.741.344 ( 2,14 % ) | 8 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| OPUS GENETICS, INC. | Director Ejecutivo | 01/11/2023 |
Voxeleron LLC
 Voxeleron LLC Packaged SoftwareTechnology Services Develops ophthalmic image analysis software | Director/Miembro de la Junta | 01/01/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
Implicit Bioscience, Inc.
 Implicit Bioscience, Inc. Pharmaceuticals: MajorHealth Technology The company is based in Seattle, WA. The company is a private biotechnology firm specializing in immunotherapy, with a focus on cardiovascular and neurodegenerative diseases. Its lead drug candidate, IC14 (atibuclimab), is a monoclonal antibody targeting CD14, a key immune system regulator that modulates multiple inflammatory pathways. IC14 acts upstream to control broad immune responses implicated in conditions such as acute decompensated heart failure, motor neurone disease/amyotrophic lateral sclerosis, acute respiratory distress syndrome, arrhythmogenic cardiomyopathy, and myocardial infarction. IC14 is in multiple phase 2 clinical trials, including studies for heart failure, COVID-19-related respiratory distress, ALS-MND, and STEMI. The company’s research includes large-scale data analyses and peer-reviewed studies validating the role of CD14 blockade in reducing immune-mediated tissue injury, particularly in cardiovascular disease. Implicit Bioscience, Inc. was founded in 2002. | Director/Miembro de la Junta | 01/01/2023 |
The Foundation Fighting Blindness, Inc.
 The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services Provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome | Corporate Officer/Principal | 01/01/2023 |
Lexitas Pharma Services , Inc.
 Lexitas Pharma Services , Inc. Miscellaneous Commercial ServicesCommercial Services Operates as an ophthalmology clinical research organization | Director Ejecutivo | 01/06/2022 |
Hovione LLC
 Hovione LLC BiotechnologyHealth Technology Develops drugs, diagnostics and other therapeutic products | Director Técnico/Científico/I+D | 01/01/2020 |
Edison Investment Research, Inc.
 Edison Investment Research, Inc. Investment ManagersFinance Provides investment research | Analyst-Equity | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 11 |
|---|---|
Implicit Bioscience, Inc.
Implicit Bioscience, Inc. Pharmaceuticals: MajorHealth Technology The company is based in Seattle, WA. The company is a private biotechnology firm specializing in immunotherapy, with a focus on cardiovascular and neurodegenerative diseases. Its lead drug candidate, IC14 (atibuclimab), is a monoclonal antibody targeting CD14, a key immune system regulator that modulates multiple inflammatory pathways. IC14 acts upstream to control broad immune responses implicated in conditions such as acute decompensated heart failure, motor neurone disease/amyotrophic lateral sclerosis, acute respiratory distress syndrome, arrhythmogenic cardiomyopathy, and myocardial infarction. IC14 is in multiple phase 2 clinical trials, including studies for heart failure, COVID-19-related respiratory distress, ALS-MND, and STEMI. The company’s research includes large-scale data analyses and peer-reviewed studies validating the role of CD14 blockade in reducing immune-mediated tissue injury, particularly in cardiovascular disease. Implicit Bioscience, Inc. was founded in 2002. | Health Technology |
Medical University of South Carolina
 Medical University of South Carolina Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Citadel, The Military College of South Carolina
 The Citadel, The Military College of South Carolina Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clemson University
 Clemson University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hovione LLC
Hovione LLC BiotechnologyHealth Technology Develops drugs, diagnostics and other therapeutic products | Health Technology |
The Foundation Fighting Blindness, Inc.
The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services Provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome | Commercial Services |
Edison Investment Research, Inc.
Edison Investment Research, Inc. Investment ManagersFinance Provides investment research | Finance |
Ocuphire Pharma, Inc.
 Ocuphire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceuticals for eye disorders | Health Technology |
Voxeleron LLC
Voxeleron LLC Packaged SoftwareTechnology Services Develops ophthalmic image analysis software | Technology Services |
Lexitas Pharma Services , Inc.
Lexitas Pharma Services , Inc. Miscellaneous Commercial ServicesCommercial Services Operates as an ophthalmology clinical research organization | Commercial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
